Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
McKesson
Johnson and Johnson
Baxter
McKinsey

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,078,188

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,078,188
Title:MUC17 encoding nucleic acid sequences, polypeptides, antibodies and methods of use thereof
Abstract: Disclosed herein are human MUC17-encoding nucleotide sequences, proteins, antibodies, and methods for use thereof.
Inventor(s): Batra; Surinder (Omaha, NE), Moniaux; Nicolas (Omaha, NE)
Assignee: Board of Regents of the University of Nebraska (Lincoln, NE)
Application Number:10/704,781
Patent Claims:1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a mucin 17 (MUC17) polypeptide, wherein said MUC17 polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 4.

2. The isolated nucleic acid molecule of claim 1, wherein said MUC17 polypeptide has the amino acid sequence of SEQ ID NO: 3.

3. The isolated nucleic acid molecule of claim 1, wherein said MUC17 polypeptide has the amino acid sequence of SEQ ID NO: 4.

4. The isolated nucleic acid molecule of claim 1, wherein said nucleotide sequence is SEQ ID NO: 1.

5. The isolated nucleic acid molecule of claim 1, wherein said nucleotide sequence is sequence of SEQ ID NO: 2.

6. The isolated nucleic acid of claim 1, which is DNA.

7. The isolated nucleic acid of claim 6, which is a cDNA encoding a MUC17 polypeptide.

8. The isolated nucleic acid of claim 6, which is a gene comprising introns and exons, said exons encoding said MUC17 polypeptide of SEQ ID NO: 3 or SEQ ID NO: 4, and said nucleic acid sequence having the intron exon junctions of Table I.

9. An isolated RNA molecule transcribed from the nucleic acid of claim 6.

10. An isolated plasmid comprising the nucleic acid molecule of claim 1.

11. An isolated vector comprising the nucleic acid molecule of claim 1.

12. An isolated retroviral vector comprising the nucleic acid molecule of claim 1.

13. An isolated host cell comprising the nucleic acid molecule of claim 1.

14. The isolated host cell of claim 13, wherein said host cell is selected from the group consisting of bacterial, fungal, mammalian, insect and plant cells.

15. The isolated host cell of claim 13, wherein said nucleic acid molecule is provided in a plasmid and is operably linked to mammalian regulatory elements in reverse, antisense orientation.

16. A method for diagnosing pancreatic cancer in a patient comprising: a) measuring the level of the nucleic acid molecule encoding MUC17 of claim 1 in a biological sample from said patient; and b) comparing said level of said MUC 17 nucleic acid molecule from said patient with that from a healthy subject, wherein an elevation of said level of said MUC17 nucleic acid molecule from said patient is indicative that said patient has pancreatic cancer.

17. The method of claim 16, wherein said MUC17 nucleic acid molecule is an mRNA which encodes a MUC17 protein having a sequence of SEQ ID NO: 3.

18. The method of claim 16, wherein said MUC17 nucleic acid molecule is an mRNA which encodes a MUC17 protein having a sequence of SEQ ID NO: 4.

19. The method of claim 16, further comprising: c) measuring expression levels MUC4 and/or MUC12 in said biological sample from said patient; and d) comparing said expression levels MUC4 and/or MUC12 from said patient with that from said healthy subject, wherein an elevation of said expression levels of MUC4 and/or MUC12 is indicative that said patient has pancreatic cancer.

20. A kit for diagnosing pancreatic cancer in a patient comprising: a) means for isolating RNAs from a biological sample; b) means for detecting and quantifying the nucleic acid molecule of claim 1, comprising at least one nucleic acid probe consisting of a sequence selected from the group consistina of SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15; and optionally c) instructional material.

21. The kit of claim 20, wherein said nucleic acid probe further comprises a detectable label.

22. The kit of claim 20, wherein said mRNA encodes a MUC17 protein with a sequence of SEQ ID NO: 3.

23. The kit of claim 20, wherein said mRNA encodes a MUC17 protein with a sequence of SEQ ID NO: 4.

Details for Patent 7,078,188

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Board of Regents of the University of Nebraska (Lincoln, NE) 2037-11-14 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Board of Regents of the University of Nebraska (Lincoln, NE) 2037-11-14 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Board of Regents of the University of Nebraska (Lincoln, NE) 2037-11-14 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Merck
Harvard Business School
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.